Elissa Meites1, Rachel L Winer2, Michael E Newcomb3, Pamina M Gorbach4, Troy D Querec5, Jessica Rudd6, Tom Collins7, John Lin2, Janell Moore4, Thomas Remble3, Fred Swanson8, Justin Franz3, Robert K Bolan9, Matthew R Golden10, Brian Mustanski3, Richard A Crosby7, Elizabeth R Unger5, Lauri E Markowitz1. 1. Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. 2. Department of Epidemiology, University of Washington, Seattle, Washington, USA. 3. Institute for Sexual and Gender Minority Health and Wellbeing and Department of Medical Social Sciences, Northwestern University and Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. 4. Department of Epidemiology, Fielding School of Public Health, University of California at Los Angeles, Los Angeles, California, USA. 5. Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA. 6. Maximus Services LLC, CDC Contractor, Atlanta, Georgia, USA. 7. College of Public Health, University of Kentucky, Lexington, Kentucky, USA. 8. Gay City Health Project, Seattle, Washington, USA. 9. Los Angeles LGBT Center, Los Angeles, California, USA. 10. Center for AIDS & STD, University of Washington, Seattle, Washington, USA.
Abstract
BACKGROUND: In the United States, human papillomavirus (HPV) vaccination has been recommended for young adult men who have sex with men (MSM) since 2011. METHODS: The Vaccine Impact in Men study surveyed MSM and transgender women aged 18-26 years in 3 US cities during 2016-2018. Self-collected anal swab and oral rinse specimens were assessed for 37 types of HPV. We compared HPV prevalence among vaccinated and unvaccinated participants and determined adjusted prevalence ratios (aPR) and 95% confidence intervals (CI). RESULTS: Among 1767 participants, 704 (39.8%) self-reported receiving HPV vaccine. Median age at vaccination (18.7 years) was older than age at first sex (15.7 years). Quadrivalent vaccine-type HPV was detected in anal or oral specimens from 475 (26.9%) participants. Vaccine-type HPV prevalence was lower among vaccinated (22.9%) compared with unvaccinated (31.6%) participants; aPR for those who initiated vaccination at age ≤18 years was 0.41 (CI, 0.24-0.57) and at age >18 years was 0.82 (CI, 0.67-0.98). Vaccine effectiveness of at least 1 HPV vaccine dose at age ≤18 years or >18 years was 59% and 18%, respectively. CONCLUSIONS: Findings suggest real-world effectiveness of HPV vaccination among young adult MSM. This effect was stronger with younger age at vaccination. Published by Oxford University Press for the Infectious Diseases Society of America 2020.
BACKGROUND: In the United States, human papillomavirus (HPV) vaccination has been recommended for young adult men who have sex with men (MSM) since 2011. METHODS: The Vaccine Impact in Men study surveyed MSM and transgender women aged 18-26 years in 3 US cities during 2016-2018. Self-collected anal swab and oral rinse specimens were assessed for 37 types of HPV. We compared HPV prevalence among vaccinated and unvaccinated participants and determined adjusted prevalence ratios (aPR) and 95% confidence intervals (CI). RESULTS: Among 1767 participants, 704 (39.8%) self-reported receiving HPV vaccine. Median age at vaccination (18.7 years) was older than age at first sex (15.7 years). Quadrivalent vaccine-type HPV was detected in anal or oral specimens from 475 (26.9%) participants. Vaccine-type HPV prevalence was lower among vaccinated (22.9%) compared with unvaccinated (31.6%) participants; aPR for those who initiated vaccination at age ≤18 years was 0.41 (CI, 0.24-0.57) and at age >18 years was 0.82 (CI, 0.67-0.98). Vaccine effectiveness of at least 1 HPV vaccine dose at age ≤18 years or >18 years was 59% and 18%, respectively. CONCLUSIONS: Findings suggest real-world effectiveness of HPV vaccination among young adult MSM. This effect was stronger with younger age at vaccination. Published by Oxford University Press for the Infectious Diseases Society of America 2020.
Entities:
Keywords:
papillomavirus infections; papillomavirus vaccines; sexual and gender minorities; vaccination
Authors: Dorothy A Machalek; Mary Poynten; Fengyi Jin; Christopher K Fairley; Annabelle Farnsworth; Suzanne M Garland; Richard J Hillman; Kathy Petoumenos; Jennifer Roberts; Sepehr N Tabrizi; David J Templeton; Andrew E Grulich Journal: Lancet Oncol Date: 2012-03-23 Impact factor: 41.316
Authors: Camiel A H Welling; Sofie H Mooij; Marianne A B van der Sande; Martijn S van Rooijen; Wilma F Vermeulen-Oost; Audrey J King; Arne van Eeden; Daniëlle A M Heideman; Ineke G Stolte; Maarten F Schim van der Loeff Journal: Sex Transm Dis Date: 2015-06 Impact factor: 2.830
Authors: Lauri E Markowitz; Eileen F Dunne; Mona Saraiya; Harrell W Chesson; C Robinette Curtis; Julianne Gee; Joseph A Bocchini; Elizabeth R Unger Journal: MMWR Recomm Rep Date: 2014-08-29
Authors: Eva Herweijer; Karin Sundström; Alexander Ploner; Ingrid Uhnoo; Pär Sparén; Lisen Arnheim-Dahlström Journal: Int J Cancer Date: 2016-03-09 Impact factor: 7.396
Authors: Elissa Meites; Peter G Szilagyi; Harrell W Chesson; Elizabeth R Unger; José R Romero; Lauri E Markowitz Journal: MMWR Morb Mortal Wkly Rep Date: 2019-08-16 Impact factor: 17.586
Authors: Raiza Amiling; Rachel L Winer; Michael E Newcomb; Pamina M Gorbach; John Lin; Richard A Crosby; Brian Mustanski; Lauri E Markowitz; Elissa Meites Journal: Hum Vaccin Immunother Date: 2021-12-02 Impact factor: 4.526
Authors: Rachel L Winer; John Lin; Troy D Querec; Elizabeth R Unger; Joshua E Stern; Jessica M Rudd; Matthew R Golden; Fred Swanson; Lauri E Markowitz; Elissa Meites Journal: J Infect Dis Date: 2022-02-01 Impact factor: 5.226
Authors: Terra Forward; Elissa Meites; John Lin; James P Hughes; Elizabeth R Unger; Lauri E Markowitz; Matthew Golden; Fred Swanson; Paul M Faestel; Rachel L Winer Journal: Sex Transm Dis Date: 2022-01-01 Impact factor: 2.830
Authors: Cintia Muñoz-Quiles; Javier Díez-Domingo; Luis Acedo; Víctor Sánchez-Alonso; Rafael J Villanueva Journal: Viruses Date: 2021-05-13 Impact factor: 5.048
Authors: Catharine Chambers; Shelley L Deeks; Rinku Sutradhar; Joseph Cox; Alexandra de Pokomandy; Troy Grennan; Trevor A Hart; Gilles Lambert; David M Moore; François Coutlée; Ann N Burchell Journal: Sex Transm Dis Date: 2022-02-01 Impact factor: 2.830